Gene editing firm Cibus misses Q3 revenue estimates

Cibus

13/11/2025 21:24

Overview

Cibus Q3 revenue misses analyst expectations, reporting $615,000 compared to $1.39 mln estimate

Net loss for Q3 was $24.3 mln, significantly lower than $201.5 mln last year

Company focuses on strategic partnerships and cost reductions to support future growth

Outlook

Cibus targets initial commercial launch of rice traits in Latin America by 2027

Company plans commercial expansion of Sustainable Ingredients program in 2026

Cibus aims to reduce annual net cash usage to $30 mln by 2026

Result Drivers

LATAM EXPANSION - Cibus continues to progress with herbicide tolerance traits in Rice, targeting initial commercial launches in Latin America by 2027

INDIA MARKET ENTRY - Cibus engaged AgVayā to support entry into Indian market for advanced gene editing solutions

BIOFRAGRANCE PILOT - Successfully completed pre-commercial pilot runs for biofragrance products, targeting commercial expansion in 2026

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Miss
$615,000
$1.39 mln (3 Analysts)
Q3 EPS
-$0.44
Q3 Net Income
-$24.30 mln
Q3 Income from Operations
-$15.44 mln
Q3 Operating Expenses
$16.05 mln
Q3 Pretax Profit
-$24.31 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

Wall Street's median 12-month price target for Cibus Inc is $15.50, about 91.3% above its November 12 closing price of $1.35

Press Release: ID:nGNX3yN8qv

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)